Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2009

Open Access 01-12-2009 | Research

δ-Catenin promotes prostate cancer cell growth and progression by altering cell cycle and survival gene profiles

Authors: Yan Zeng, Agustin Abdallah, Jian-Ping Lu, Tao Wang, Yan-Hua Chen, David M Terrian, Kwonseop Kim, Qun Lu

Published in: Molecular Cancer | Issue 1/2009

Login to get access

Abstract

Background

δ-Catenin is a unique member of β-catenin/armadillo domain superfamily proteins and its primary expression is restricted to the brain. However, δ-catenin is upregulated in human prostatic adenocarcinomas, although the effects of δ-catenin overexpression in prostate cancer are unclear. We hypothesized that δ-catenin plays a direct role in prostate cancer progression by altering gene profiles of cell cycle regulation and cell survival.

Results

We employed gene transfection and small interfering RNA to demonstrate that increased δ-catenin expression promoted, whereas its knockdown suppressed prostate cancer cell viability. δ-Catenin promoted prostate cancer cell colony formation in soft agar as well as tumor xenograft growth in nude mice. Deletion of either the amino-terminal or carboxyl-terminal sequences outside the armadillo domains abolished the tumor promoting effects of δ-catenin. Quantitative RT2 Profiler™ PCR Arrays demonstrated gene alterations involved in cell cycle and survival regulation. δ-Catenin overexpression upregulated cyclin D1 and cdc34, increased phosphorylated histone-H3, and promoted the entry of mitosis. In addition, δ-catenin overexpression resulted in increased expression of cell survival genes Bcl-2 and survivin while reducing the cell cycle inhibitor p21Cip1.

Conclusion

Taken together, our studies suggest that at least one consequence of an increased expression of δ-catenin in human prostate cancer is the alteration of cell cycle and survival gene profiles, thereby promoting tumor progression.
Appendix
Available only for authorised users
Literature
1.
Chesire DR, Isaacs WB: Beta-catenin signaling in prostate cancer: an early perspective. Endocr Relat Cancer. 2003, 10: 537-560. 10.1677/erc.0.0100537CrossRefPubMed
2.
Aoki K, Taketo MM: Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci. 2007, 120: 3327-3335. 10.1242/jcs.03485CrossRefPubMed
3.
Lu Q, Paredes M, Medina M, Zhou JH, Cavallo R, Peifer M, Orecchio L, Kosik KS: delta-catenin, an adhesive junction-associated protein which promotes cell scattering. J Cell Biol. 1999, 144: 519-532. 10.1083/jcb.144.3.519PubMedCentralCrossRefPubMed
4.
Ho C, Zhou J, Medina M, Goto T, Jacobson M, Bhide PG, Kosik KS: delta-catenin is a nervous system-specific adherens junction protein which undergoes dynamic relocalization during development. J Comp Neurol. 2000, 420: 261-276. 10.1002/(SICI)1096-9861(20000501)420:2<261::AID-CNE8>3.0.CO;2-QCrossRefPubMed
5.
Paffenholz R, Franke WW: Identification and localization of a neurally expressed member of the plakoglobin/armadillo multigene family. Differentiation. 1997, 61: 293-304. 10.1046/j.1432-0436.1997.6150293.xCrossRefPubMed
6.
Zhou J, Liyanage U, Medina M, Ho C, Simmons AD, Lovett M, Kosik KS: Presenilin 1 interaction in the brain with a novel member of the Armadillo family. Neuroreport. 1997, 8: 2085-90.CrossRefPubMed
7.
Peifer M, Berg S, Reynolds AB: A repeating amino acid motif shared by proteins with diverse cellular roles. Cell. 1994, 76: 789-791. 10.1016/0092-8674(94)90353-0CrossRefPubMed
8.
9.
Lu Q, Dobbs LJ, Gregory CW, Lanford GW, Revelo MP, Shappell S, Chen YH: Increased expression of delta-catenin/neural plakophilin-related armadillo protein is associated with the down-regulation and redistribution of E-cadherin and p120ctn in human prostate cancer. Hum Patho. 2005, 36: 1037-1048. 10.1016/j.humpath.2005.07.012. 10.1016/j.humpath.2005.07.012CrossRef
10.
11.
Chartier NT, Oddou CI, Lainé MG, Ducarouge B, Marie CA, Block MR, Jacquier-Sarlin MC: Cyclin-dependent kinase 2/cyclin E complex is involved in p120 catenin (p120ctn)-dependent cell growth control: a new role for p120ctn in cancer. Cancer Res. 2007, 67: 9781-90. 10.1158/0008-5472.CAN-07-0233PubMedCentralCrossRefPubMed
12.
Kim K, Oh M, Ki H, Wang T, Bareiss S, Fini ME, Li D, Lu Q: Identification of E2F1 as a positive transcriptional regulator for δ-catenin. Biochem Biophys Res Commun. 2008, 369: 414-420. 10.1016/j.bbrc.2008.02.069PubMedCentralCrossRefPubMed
13.
Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, Resnick MI, Bodner DR, Jacobberger JW, Delmoro CM, Giaconia JM: Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst. 1998, 85: 394-398. 10.1093/jnci/85.5.394. 10.1093/jnci/85.5.394CrossRef
14.
Sramkoski RM, Pretlow TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW: A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell. Dev Biol Anim. 1999, 35: 403-409. 10.1007/s11626-999-0115-4. 10.1007/s11626-999-0115-4CrossRef
15.
Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979, 17: 16-23.PubMed
16.
Gazdar AF, Minna JD: NCI series of cell lines: an historical perspective. J Cell Biochem. 1996, 24 (Suppl): 1-11. 10.1002/jcb.240630502. 10.1002/jcb.240630502CrossRef
17.
Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG: CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res. 1996, 56: 3042-3046.PubMed
18.
Kim K, Sirota A, Chen YH, Jones SB, Dudek R, Lanford GW, Thakore C, Lu Q: Dendrite-like process formation and cytoskeletal remodeling regulated by delta-catenin expression. Exp Cell Res. 2002, 275: 171-184. 10.1006/excr.2002.5503CrossRefPubMed
19.
Jones SB, Lanford GW, Chen YH, Morabito M, Kim K, Lu Q: Glutamate-induced delta-catenin redistribution and dissociation from postsynaptic receptor complexes. Neuroscience. 2002, 115: 1009-1021. 10.1016/S0306-4522(02)00532-8CrossRefPubMed
20.
King RW, Deshaies RJ, Peters JM, Kirschner MW: How proteolysis drives the cell cycle. Science. 1996, 274: 1652-1659. 10.1126/science.274.5293.1652CrossRefPubMed
21.
Ogata Y, Takahashi M: Bcl-xL as an antiapoptotic molecule for cardiomyocytes. Drug News Perspect. 2004, 16: 446-452. 10.1358/dnp.2003.16.7.829356. 10.1358/dnp.2003.16.7.829356CrossRef
22.
Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ, McCauley L, Shi S, Chen S, Wang CY: NF-kappa-B in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nature Med. 2007, 13: 62-69. 10.1038/nm1519CrossRefPubMed
23.
Mathupala SP, Heese C, Pedersen PL: Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem. 1997, 272: 22776-22780. 10.1074/jbc.272.36.22776CrossRefPubMed
24.
El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B: WAF1/CIP1 is induced in p53 mediated G1 arrest and apoptosis. Cancer Res. 1994, 54: 1169-1174.PubMed
25.
Graña X, Reddy EP: Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995, 11: 211-219.PubMed
26.
Burger MJ, Tebay MA, Keith PA, Samaratunga HM, Clements J, Lavin MF, Gardiner RA: Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int J Cancer. 2002, 100: 228-237. 10.1002/ijc.10468CrossRefPubMed
27.
Huang FY, Chiu PM, Tam KF, Kwok YK, Lau ET, Tang MH, Ng TY, Liu VW, Cheung AN, Ngan HY, Duparc RH, Boutemmine D, Champagne MP, Tetreault N, Bernier G: Semi-quantitative fluorescent PCR analysis identifies PRKAA1 on chromosome 5 as a potential candidate cancer gene of cervical cancer. Gynecol Oncol. 2006, 103 (1): 219-225. 10.1016/j.ygyno.2006.02.028CrossRefPubMed
28.
Zheng M, Simon R, Mirlacher M, Maurer R, Gasser T, Forster T, Diener PA, Mihatsch MJ, Sauter G, Schraml P: TRIO amplification and abundant mRNA expression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Am J Pathol. 2004, 165 (1): 63-69.PubMedCentralCrossRefPubMed
29.
Duparc RH, Boutemmine D, Champagne MP, Tétreault N, Bernier G: Pax6 is required for delta-catenin/neurojungin expression during retinal, cerebellar and cortical development in mice. Dev Biol. 2006, 300 (2): 647-655. 10.1016/j.ydbio.2006.07.045CrossRefPubMed
30.
Wang T, Chen YH, Hong H, Zeng Y, Zhang J, Lu JP, Jeansonne B, Lu Q: Increased nucleotide polymorphic changes in the 5'-untranslated region of δ-catenin (CTNND2) gene in prostate cancer. Oncogene. 2009, 28 (4): 555-564. 10.1038/onc.2008.399PubMedCentralCrossRefPubMed
31.
Lu Q, Mukhopadhyay NK, Griffin JD, Paredes M, Medina M, Kosik KS: Brain armadillo protein delta-catenin interacts with Abl tyrosine kinase and modulates cellular morphogenesis in response to growth factors. J Neurosci Res. 2002, 67: 618-624. 10.1002/jnr.10151CrossRefPubMed
32.
Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, Feng B, Zhao JJ, Roberts TM, Mandel G, Hannon GJ, Depinho RA, Chin L, Elledge SJ: A genetic screen for candidate tumor suppressors identifies REST. Cell. 2005, 121: 837-848. 10.1016/j.cell.2005.03.033CrossRefPubMed
33.
Martinez MC, Ochiishi T, Majewski M, Kosik KS: Dual regulation of neuronal morphogenesis by a delta-catenin-cortactin complex and Rho. J Cell Biol. 2003, 162: 99-111. 10.1083/jcb.200211025PubMedCentralCrossRefPubMed
34.
Kim H, Han JR, Park J, Oh M, James SE, Chang S, Lu Q, Lee KY, Ki H, Song WJ, Kim K: delta-Catenin-induced dendritic morphogenesis: an essential role of p190RhoGEF interaction through Akt1-mediated phosphorylation. J Biol Chem. 2008, 283: 977-987. 10.1074/jbc.M707158200PubMedCentralCrossRefPubMed
35.
Goel A, Mathupala SP, Pedersen PL: Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression. J Biol Chem. 2003, 278: 15333-15340. 10.1074/jbc.M300608200CrossRefPubMed
36.
Mathupala SP, Ko YH, Pedersen PL: Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 2006, 25: 4777-4786. 10.1038/sj.onc.1209603PubMedCentralCrossRefPubMed
37.
Mori A, Lehmann S, O'Kelly J, Kumagai T, Desmond JC, Pervan M, McBride WH, Kizaki M, Koeffler HP: Capsaicin, a component of red peppers, inhibits growth of androgen-independent, p53 mutant prostate cancer cells. Cancer Res. 2006, 66: 3222-3229. 10.1158/0008-5472.CAN-05-0087CrossRefPubMed
Metadata
Title
δ-Catenin promotes prostate cancer cell growth and progression by altering cell cycle and survival gene profiles
Authors
Yan Zeng
Agustin Abdallah
Jian-Ping Lu
Tao Wang
Yan-Hua Chen
David M Terrian
Kwonseop Kim
Qun Lu
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2009
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-8-19

Other articles of this Issue 1/2009

Molecular Cancer 1/2009 Go to the issue

Research

Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis

Research

Molecular assays for the detection of microRNAs in prostate cancer

Research

Vesnarinone downregulates CXCR4 expression via upregulation of Krüppel-like factor 2 in oral cancer cells

Research

Dual effects of TGF-β on ERα-mediated estrogenic transcriptional activity in breast cancer

Research

The sonic hedgehog signaling pathway is reactivated in human renal cell carcinoma and plays orchestral role in tumor growth

Research

A universal assay for detection of oncogenic fusion transcripts by oligo microarray analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits